SCHEMBL1387883

SCHEMBL1387883

O=C=CCc1ccc(O)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 3/20 0.44
ESR2 Q92731 2/20 0.44
CA2 P00918 3/20 0.41
CAMK2A Q9UQM7 1/20 0.41
ABAT P80404 1/20 0.41
TMEM97 Q5BJF2 1/20 0.39
SIGMAR1 Q99720 1/20 0.39
KDM4E B2RXH2 2/20 0.38
F13A1 P00488 1/20 0.38
IDO1 P14902 2/20 0.38
ALDH1A1 P00352 1/20 0.38
HTR1A P08908 1/20 0.38
ADRA2A P08913 1/20 0.38
SLC6A2 P23975 1/20 0.38
CYP2C19 P33261 1/20 0.38
HTR3A P46098 1/20 0.38
BACE1 P56817 1/20 0.38
TAAR1 Q96RJ0 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
TRPA1 O75762 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7569322 0.77 IDO1 (0.41) CA2IDO1ALDH1A1TAAR1KMT2A
SCHEMBL5699094 0.77 TRPA1 (0.42) IDO1TAAR1TRPA1
SCHEMBL1387882 0.77 ESR1 (0.44) ESR1ESR2CA2CAMK2AABAT
SCHEMBL6712931 0.77 XDH (0.57) ESR1CA2KDM4EALDH1A1HTR1A
SCHEMBL57808 0.76 MAOB (0.52) CA2IDO1
SCHEMBL7103399 0.76 ESR1 (0.70) ESR1ESR2CA2CAMK2AABAT
SCHEMBL6599690 0.76 CYP2A6 (0.39) ABATKDM4EALDH1A1KMT2A
SCHEMBL105690 0.75 ESR1 (0.52) ESR1ESR2CA2CAMK2AABAT
SCHEMBL27814917 0.75 ESR1 (0.52) ESR1ESR2CA2CAMK2AABAT
SCHEMBL28140503 0.75 ENPP2 (0.48) CA2KDM4EIDO1ALDH1A1TAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130045942-A1 N6-SUBSTITUTED ADENOSINE DERIVATIVES AND N6-SUBSTITUTED ADENINE DERIVATIVES AND USES THEREOF INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2013-02-21 US claimed
EP-2511283-A1 N6-SUBSTITUTED ADENOSINE DERIVATIVES, N6-SUBSTITUTED ADENINE DERIVATIVES AND USES THEREOF INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2012-10-17 EP claimed
EP-0994176-B1 Single phase liquid mixture of benzophenone and mixture of at least two other normally solid perfumery substances and perfumery uses thereof INT FLAVORS & FRAGRANCES INC (US) 2004-01-28 EP claimed
EP-0994176-A2 Single phase liquid mixture of benzophenone and mixture of at least two other normally solid perfumery substances and perfumery uses thereof INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) 2000-04-19 EP claimed
JP-H08509967-A 1996-10-22 JP claimed
EP-0691959-A1 HETEROCYCLIC DERIVATIVES AS PLATELET AGGREGATION INHIBITORS ZENECA LIMITED (GB) 1996-01-17 EP claimed
EP-0690847-A1 HETEROCYCLIC COMPOUNDS AS PLATELET AGGREGATION INHIBITORS ZENECA LIMITED (GB) 1996-01-10 EP claimed
WO-1994022835-A2 HETEROCYCLIC COMPOUNDS AS PLATELET AGGREGATION INHIBITORS ZENECA LIMITED (GB) 1994-10-13 WO claimed
WO-1994022834-A1 HETEROCYCLIC DERIVATIVES AS PLATELET AGGREGATION INHIBITORS ZENECA LIMITED (GB) 1994-10-13 WO claimed
JP-7041452-A None JP disclosed
JP-7041452-A None JP disclosed
US-10174033-B2 N6-substituted adenosine derivatives and N6-substituted adenine derivatives and uses thereof INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2019-01-08 US disclosed
US-20160367691-A1 TARGETED ENZYME COMPOUNDS AND USES THEREOF ANGIOCHEM INC (CA) 2016-12-22 US disclosed
US-20130045942-A1 N6-SUBSTITUTED ADENOSINE DERIVATIVES AND N6-SUBSTITUTED ADENINE DERIVATIVES AND USES THEREOF INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2013-02-21 US disclosed
EP-0691959-A1 HETEROCYCLIC DERIVATIVES AS PLATELET AGGREGATION INHIBITORS ZENECA LIMITED (GB) 1996-01-17 EP disclosed
EP-0690847-A1 HETEROCYCLIC COMPOUNDS AS PLATELET AGGREGATION INHIBITORS ZENECA LIMITED (GB) 1996-01-10 EP disclosed
JP-H0741452-A PRODUCTION OF 4-(3-OXOALKYL)PHENOL CHISSO CORP 1995-02-10 JP disclosed
JP-H0741452-A PRODUCTION OF 4-(3-OXOALKYL)PHENOL CHISSO CORP 1995-02-10 JP disclosed
WO-1994022835-A2 HETEROCYCLIC COMPOUNDS AS PLATELET AGGREGATION INHIBITORS ZENECA LIMITED (GB) 1994-10-13 WO disclosed
WO-1994022834-A1 HETEROCYCLIC DERIVATIVES AS PLATELET AGGREGATION INHIBITORS ZENECA LIMITED (GB) 1994-10-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160367691-A1 TARGETED ENZYME COMPOUNDS AND USES THEREOF GAA, CTSS, CTSB ESR1 4174/4885ESR2 3796/4885CA2 1185/4885
US-10174033-B2 N6-substituted adenosine derivatives and N6-substituted adenine derivatives and uses thereof ADORA2A, ADORA3, ADORA1 ESR1 2260/4885ESR2 3107/4885CA2 3762/4885
US-20130045942-A1 N6-SUBSTITUTED ADENOSINE DERIVATIVES AND N6-SUBSTITUTED ADENINE DERIVATIVES AND USES THEREOF ADORA2A, ADORA3, ADORA1 ESR1 2260/4885ESR2 3107/4885CA2 3762/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.